Skip to main content

Table 4 Comparison of the incidence of adverse reactions

From: Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer

 

Research group

Control group

P

Myelosuppression (case, %)

6 (13.3%)

7 (15.6%)

1.000

Hypothyroidism (case, %)

5 (11.1%)

7 (15.6%)

0.756

High blood pressure (case, %)

7 (15.6%)

5 (11.1%)

0.756

Dermatotoxicity (case, %)

6 (13.3%)

5 (11.1%)

1.000